首页> 外文期刊>Pharmacogenetics and genomics >Toll-like receptor 4 gene polymorphisms show no association with the risk of clinical or angiographic restenosis after percutaneous coronary intervention.
【24h】

Toll-like receptor 4 gene polymorphisms show no association with the risk of clinical or angiographic restenosis after percutaneous coronary intervention.

机译:Toll样受体4基因多态性与经皮冠状动脉介入治疗后发生临床或血管造影再狭窄的风险无关。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: Restenosis after percutaneous coronary intervention (PCI) remains an issue even in the drug-eluting stent era. Genetic polymorphisms may provide insight in the pathogenesis of restenosis and may help in the stratification of patients at risk for restenosis. The aim of this study was to examine whether polymorphisms at the toll-like receptor 4 (TLR4) locus, that are associated with impaired innate immune system and with an increased risk of cardiovascular events, were associated with clinical and/or angiographic restenosis after PCI. METHODS: The GENetic Determinants of Restenosis (GENDER) project was a prospective, multicenter study that enrolled 3146 consecutive patients after successful PCI. Frequencies of the TLR4 896A/G (Asp299Gly; rs4986790) and 1196C/T (Thr399Ile; rs4986791) polymorphisms and haplotypes were assessed. Patients were followed up for 1 year and in a subgroup of 406 patients angiographic follow-up was obtained. RESULTS: We included a total of 2682 patients that underwent successful PCI. There was no association between genotypes and the risk of target vessel revascularization at 1-year or late luminal loss at 6-months angiographic follow-up (P=0.53 and 0.44, respectively). Absence of association with target lesion revascularization and late luminal loss was replicated in the GEnetic risk factors for In-Stent Hyperplasia study Amsterdam (GEISHA) cohort study of 674 patients and in a subgroup of 550 patients with angiographic follow-up available (P=0.26, and 0.86, respectively). Moreover, in both the studies, no significant differences between haplotypes A/C and G/T were observed for target vessel revascularization at late luminal loss. CONCLUSION: Although inflammation has been implicated in the pathophysiology of restenosis, the 896A/G and 1196C/T polymorphisms or haplotypes based on these polymorphisms at the TLR4 locus are not associated with an increased risk of target vessel revascularization or angiographic restenosis after PCI. These polymorphisms are not useful for pre-PCI identification of patients at risk for restenosis.
机译:目的:即使在药物洗脱支架时代,经皮冠状动脉介入治疗(PCI)后的再狭窄仍然是一个问题。遗传多态性可以为再狭窄的发病机理提供见解,并且可以帮助对处于再狭窄风险中的患者进行分层。这项研究的目的是检查与Toll样受体4(TLR4)位点相关的多态性与PCI后的临床和/或血管造影再狭窄是否相关,这些基因多态性与先天免疫系统受损和心血管事件风险增加相关。方法:再狭窄的遗传决定因素(GENDER)项目是一项前瞻性,多中心研究,成功纳入了PCI后3146名连续患者。评估了TLR4 896A / G(Asp299Gly; rs4986790)和1196C / T(Thr399Ile; rs4986791)多态性和单倍型的频率。对患者进行了1年的随访,并在406名患者的亚组中进行了血管造影随访。结果:我们纳入了总共2682例成功行PCI的患者。在1年或6个月的血管造影随访中,管腔丢失的基因型与靶血管血运重建的风险之间没有关联(分别为P = 0.53和0.44)。在针对支架内增生研究的阿姆斯特丹市(GEISHA)队列研究的674位患者和550例血管造影随访患者的亚组中,与靶病变血运重建和晚期管腔丢失无关的研究重复出现(P = 0.26) ,和分别为0.86)。此外,在两项研究中,在晚期管腔丢失时,对于靶血管血运重建,单倍型A / C和G / T之间均未观察到显着差异。结论:尽管炎症与再狭窄的病理生理有关,但基于TLR4基因座的896A / G和1196C / T多态性或单倍型与PCI后靶血管血运重建或血管造影再狭窄的风险增加无关。这些多态性对于PCI前识别有再狭窄风险的患者没有用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号